Dr. Robert Huizinga reports

KANE BIOTECH ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Kane Biotech Inc. has released the voting results from its annual and special meeting of shareholders held on June 24, 2026. A total of 83,622,028 common shares were represented at the meeting, representing approximately 46 per cent of the company's issued and outstanding common shares as of the record date of the meeting. All matters voted upon at the meeting were approved by shareholders, as detailed below.

Election of directors

All six nominees listed in the company's management information circular dated May 8, 2026, were elected as directors of the company. The voting results are set out below.

Appointment of auditor

At the meeting, shareholders approved the appointment of MNP LLP as auditor of the company for the ensuing year and the directors were authorized to fix the remuneration to be paid to the auditor.

Approval of the fifth amended and restated performance and restricted share unit (PRSU) plan

At the meeting, shareholders approved the company's fifth amended and restated performance and restricted share unit plan. The company's board of directors approved the amended and restated PRSU plan on May 8, 2026. Under the amended and restated PRSU plan, the maximum number of common shares that are reserved for issuance is equal to the number of common shares representing 10 per cent of the total common shares issued and outstanding as at the date of the approval of the amended and restated PRSU plan by the board, being 18,185,656 common shares.

A copy of the amended and restated PRSU plan was scheduled to the circular and is available under the company's SEDAR+ profile.

Approval of the fourth amended and restated stock option plan

At the meeting, shareholders approved the company's fourth amended and restated stock option plan. The company's board of directors approved the amended and restated stock option plan on May 8, 2026. Under the amended and restated stock option plan, the maximum number of common shares that are reserved for issuance is equal to the number of common shares representing 10 per cent of the total common shares issued and outstanding as at the date of grant or issuance of any security-based compensation.

A copy of the amended and restated stock option plan was scheduled to the circular and is available under the company's SEDAR+ profile.

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel, revyve anti-microbial wound gel spray and revyve anti-microbial skin and wound cleanser are all U.S. FDA (U.S. Food and Drug Administration) 510(k) cleared. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are also Health Canada approved.

We seek Safe Harbor.